Barclays PLC Atreca, Inc. Transaction History

Barclays PLC

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	SELL	$0.78 - $1.68 $1,123 - $2,420	-1,441 Reduced 2.95%	47,487 $38,000
Q3 2022 Nov 03, 2022	SELL	$1.59 - $2.74 $3,049 - $5,255	-1,918 Reduced 3.77%	48,928 $77,000
Q2 2022 Aug 12, 2022	SELL	$1.56 - $3.25 $6,581 - $13,711	-4,219 Reduced 7.66%	50,846 $91,000
Q1 2022 May 16, 2022	SELL	$1.61 - $5.2 $17,178 - $55,484	-10,670 Reduced 16.23%	55,065 $174,000
Q4 2021 Feb 14, 2022	BUY	$2.87 - $6.29 $96,087 - $210,589	33,480 Added 103.8%	65,735 $199,000
Q3 2021 Nov 09, 2021	BUY	$4.91 - $9.07 $99,535 - $183,867	20,272 Added 169.17%	32,255 $201,000
Q2 2021 Aug 13, 2021	SELL	$7.82 - $13.8 $136,763 - $241,348	-17,489 Reduced 59.34%	11,983 $101,000
Q1 2021 May 13, 2021	BUY	$13.0 - $19.34 $220,259 - $327,677	16,943 Added 135.23%	29,472 $452,000
Q4 2020 Feb 11, 2021	SELL	$13.03 - $17.09 $24,743 - $32,453	-1,899 Reduced 13.16%	12,529 $203,000
Q3 2020 Nov 12, 2020	BUY	$12.67 - $23.19 $16,673 - $30,518	1,316 Added 10.04%	14,428 $201,000
Q2 2020 Aug 12, 2020	BUY	$12.52 - $23.45 $74,819 - $140,137	5,976 Added 83.74%	13,112 $279,000
Q1 2020 May 13, 2020	SELL	$11.4 - $27.28 $9,496 - $22,724	-833 Reduced 10.45%	7,136 $118,000
Q4 2019 Feb 10, 2020	BUY	$9.68 - $18.67 $28,130 - $54,255	2,906 Added 57.4%	7,969 $124,000
Q3 2019 Nov 14, 2019	BUY	$10.42 - $22.04 $38,168 - $80,732	3,663 Added 261.64%	5,063 $62,000
Q2 2019 Aug 14, 2019	BUY	$17.07 - $18.84 $23,898 - $26,376	1,400 New	1,400 $25,000

30.6K

Ticker BCEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,876,000
Description
Atreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-10...

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

Stay updated on Barclays PLC with notifications on news.